The Market Opportunity
Diabetes impacts hundreds of millions of people globally. Rapid technological advances have led to increased medication options and an explosion of diabetes device adoption worldwide. Between now and 2030, experts project an 8.2% compound annual growth rate (CAGR) for the diabetes device market.
Unfortunately, the vast majority of people living with diabetes still do not have access to expert level care. There is a massive shortage of experts both in the U.S. and globally. In the U.S., there is only one endocrinologist for every 6,000 people diagnosed with diabetes. As a result, only a small percentage of patients have access to expert level care. The remaining majority either are dependent on care providers who are not equipped to deliver expert-level diabetes care, or have no access at all.
DreaMed is solving this problem by unleashing the power of AI to transform patient data into expert level treatment recommendations. DreaMed has proven AI can be used to emulate a clinical expert, and that software can be used to transform any care provider into an expert. As a result, massive amounts of patient data can now be processed and interpreted at global scale. Indeed, with this technology we can now help to ensure all patients have access to expert-level treatment recommendations when and where they need it.
DreaMed technology is cleared by the FDA, so care providers and patients can trust the treatment recommendations generated are at an expert level. The technology can be used to transform any care provider into an expert, including primary care physicians, pharmacists, RNs, PAs, diabetes educators, patients themselves and their care givers.
DreaMed’s first product launch is endo.digital, a cloud-based SAAS platform that gives care provider organizations an end-to-end diabetes care pathway that can be deployed across all care settings where patients with diabetes are treated, both remotely and in person. It is the only decision support software cleared by the FDA to support both Type 1 and Type 2 diabetes.
Diabetes device and health data uploader
Single platform to acquire patient data from the vast majority of diabetes devices on the market
FDA cleared AI enhanced decision support
Turn every provider into an expert while unifying standard of care across providers and care settings
Automated payer billing documentation
Increase revenue capture for payer CPT codes
Patient Mobile App
Increase patient engagement and adherence in between visits
EMR workflow integration
Seamless access via the patient record, and automated data push into the EMR workflow
FDA-cleared AI clinical decision support
proven to be on par with expert physicians.
(p-value < 0.01)
Nimri R et al, Nature Medicine, Vol 26(9), 2020
Nimri R et al, Diabetes Technol Ther, Vol 24(8), 2022
Nimri R et al, J Diabetes Sci Technol, Vol 16(2), 2022
Nimri R et al, Diabetes Obes Metab. 2018, Vol 20(10), 2018
Freeing Up Staff Capacity
8.9 minutes time savings per patient visit
to acquire, interpret, and document diabetes device data.
Dec 2022 – Feb 2023 pre/post time study of endo.digital deployment presented by Dr. Benaviv-Meskin, Feb 2023 at the ATTD in Berlin.
39% increase in CGM code 95251 billed to payers.
(p-value < 0.01)
2022-2023 study of customer 95251 reimbursement. N= 3465 baseline patient visits; 3527 measurement period patient visits.
*Baseline imputed based on 15% 95251 captures versus 20% actual capture post deployment
51% of patients continue using the patient app after 90 days, compared to other industry benchmarks ranging from 10% to 24%.
2022 customer data at pediatric endocrinology practice.